Get the latest news, insights, and market updates on OCUL (Ocular Therapeutix, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences
We recently published 10 Firms Shining Bright in a Bleeding Market. Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best-performing stocks on Monday. Ocular Therapeutix rallied for a second day on Monday, adding 5.22 percent to finish at $11.89 apiece as investors repositioned portfolios ahead of two healthcare conferences in the next few days. Last […] Nov 18, 2025 - $OCUL
Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run?
Ocular Therapeutix recently announced that its SOL-R registrational trial for AXPAXLI™ (OTX-TKI) in wet age-related macular degeneration reached its randomization target of 555 subjects, while simultaneously reporting third-quarter revenue of US$14.54 million and a net loss of US$69.42 million for 2025. An interesting insight is that, despite year-over-year declines in revenue and higher net losses, the company recorded strong patient retention and adherence in its clinical studies and... Nov 14, 2025 - $OCUL
Ocular Therapeutix (OCUL): Evaluating Valuation After Recent Share Price Gains
Ocular Therapeutix (OCUL) has seen its stock rise 2% in the past day, adding to investor interest after a recent stretch of gains over the past week. Year-to-date, shares have climbed over 31%. See our latest analysis for Ocular Therapeutix. The momentum behind Ocular Therapeutix is notable, with its share price accelerating more than 31% year-to-date and a solid 8.4% total shareholder return over the past year. After some recent volatility, investors seem to be warming up again, which... Nov 13, 2025 - $OCUL
Ocular Therapeutix Stock Earns 81 RS Rating
Ocular Therapeutix stock is one stock that just reached the mark, now earning a score of 81. Is Ocular Therapeutix Stock A Buy? Ocular Therapeutix stock is currently trading below its 50-day moving average, but rallying with the sector. Nov 12, 2025 - $OCUL
Ocular Therapeutix™ to Participate in November and December Investor Conferences
BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in November and December, 2025. Jefferies Global Healthcare Conference in London:Fireside Chat Date: Tuesday, November 18, 2025Fireside Chat Time: 2:30 – 2:55 PM GMTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocatio Nov 12, 2025 - $OCUL
RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is one of the 15 stocks set to explode in 2026. On November 5, 2025, RBC Capital raised its price target on Ocular Therapeutix, Inc. (NASDAQ:OCUL) from $17 to $24, while maintaining an “Outperform” rating. The revised target was attributed to the company’s strong execution in its SOL-1 wet age-related macular […] Nov 11, 2025 - $OCUL
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired non-executive employee. The award was made as an inducement material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The induce Nov 7, 2025 - $OCUL
Ocular Therapeutix (OCUL): Ongoing Losses Undermine Bullish Revenue Story Ahead of Earnings Season
Ocular Therapeutix (OCUL) remains in the red, with losses expanding at an average rate of 22.7% per year over the past five years. While the company is expected to remain unprofitable for at least the next three years and faces a negative net profit margin, analysts forecast annual revenue growth of 52.8%, far outpacing the overall US market’s projected 10.5%. Investors are left weighing these powerful growth expectations against ongoing losses, dilution risks, and a share price that trades... Nov 5, 2025 - $OCUL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple